Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

Overview of attention for article published in PharmacoEconomics, June 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 X post from an account with 721 followers.

#HealthEconJA Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” https://t.co/UifI50uZVO

07 Jun 2019

Reply Repost Favourite